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Abstract
Background—The breast cancer detection rate is a benchmark measure of screening 
mammography quality, but its computation requires linkage of mammography interpretive 
performance information with cancer incidence data. A Medicare claims-based measure of 
detected breast cancers could simplify measurement of this benchmark and facilitate 
mammography quality assessment and research.
Objectives—To validate a claims-based algorithm that can identify with high positive predictive 
value (PPV) incident breast cancers that were detected at screening mammography.
Research Design—Development of a claims-derived algorithm using classification and 
regression tree analyses within a random half-sample of Medicare screening mammography 
claims followed by validation of the algoritm in the remaining half-sample using clinical data on 
mammography results and cancer incidence from the Breast Cancer Surveillance Consortium 
(BCSC).
Subjects—Female fee-for-service Medicare enrollees age 68 years and older who underwent 
screening mammography from 2001 to 2005 within BCSC registries in four states (CA, NC, NH, 
and VT), enabling linkage of claims and BCSC mammography data (N=233,044 mammograms 
obtained by 104,997 women).
Measures—Sensitivity, specificity, and PPV of algorithmic identification of incident breast 
cancers that were detected by radiologists relative to a reference standard based on BCSC 
mammography and cancer incidence data.
Results—An algorithm based on subsequent codes for breast cancer diagnoses and treatments 
and follow-up mammography identified incident screen-detected breast cancers with 92.9% 
sensitivity (95% CI: 91.0%-94.8%), 99.9% specificity (95% CI: 99.9%-99.9%), and a PPV of 
88.0% (95% CI: 85.7%-90.4%).
Conclusions—A simple claims-based algorithm can accurately identify incident breast cancers 
detected at screening mammography among Medicare enrollees. The algorithm may enable 
mammography quality assessment using Medicare claims alone.
Keywords
Breast Cancer Screening; Mammography; Validation Studies; Medicare; Quality Assessment
INTRODUCTION
Core measures of mammography performance, such as recall rates and breast cancer 
detection rates, vary widely across U.S. radiologists and mammography facilities (1). In 
addition, despite an average recall rate in the U.S. that is nearly twice that of most European 
nations, breast cancer detection rates after screening mammography are no higher in the 
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U.S. than in Europe (2). These findings point to potentially remediable gaps in the quality of 
U.S. mammography services.
One issue may be differences in radiologist mammography experience and annual 
interpretive volume in the U.S. vs. European countries (3), and some have suggested 
benchmarks for screening mammography performance as a means of prompting radiologist- 
or facility-level efforts to improve interpretation (4, 5). The Institute of Medicine has also 
emphasized the need for high quality measures of provider- and facility-level performance 
to guide targeted quality improvement efforts (6). The U.S. Medicare program has a 
particularly large stake in mammography quality improvement. Medicare pays for over 8.5 
million mammograms each year at a cost of over $1 billion annually (7), and over half of 
incident breast cancers occur among women older than 65 years (8). Currently, Medicare 
reports facility-level performance of follow-up or recall rates as part of the Hospital Quality 
Reporting Program. However, additional valid and reliable performance measures are 
needed to facilitate broader scale improvement.
Medicare claims data are one potential data source for measuring mammography 
interpretative performance. The breast cancer detection rate, for example, is a widely used 
measure of radiologist- and facility-level interpretive performance; a cancer detection rate of 
2.5 breast cancers per 1000 screening mammograms is considered a minimally acceptable 
performance level (5). This measure, however, is challenging to implement, because it 
requires accurate identification of: 1) screening mammograms, 2) subsequent incident breast 
cancers, and 3) screening mammography interpretation. With regard to identifying screening 
mammograms using Medicare data, we recently validated a claims-based algorithm for 
distinguishing screening from diagnostic mammograms (9). The distinction between 
screening and diagnostic is critical, because the incidence of breast cancer is much higher 
following diagnostic than screening mammography (4, 10). However, with regard to the 
second step, there has been uncertainty about the accuracy of claims for identifying incident 
(rather than prevalent) breast cancers (11, 12). Diagnosis codes for breast cancer are not 
specific for incident rather than prevalent disease, and procedure codes for breast cancer 
treatments, such as mastectomy, can occur when women are treated for either benign 
conditions or recurrent breast cancer. Finally, claims provide no direct information to infer 
whether mammograms were interpreted as normal or abnormal, potentially limiting the 
ability to infer that incident cancers were detected at screening mammography.
Nattinger et al. previously validated a clinically informed, four-step algorithm for 
distinguishing incident from prevalent breast cancers using Medicare claims data (13). 
Relative to a reference standard based on Surveillance, Epidemiology, and End Results 
(SEER) cancer registry data, the algorithm achieved a sensitivity of ~80% and a positive 
predictive value of over 90%. However, the algorithm was not validated in a cohort 
undergoing screening mammography, so it is uncertain if the algorithm accurately identifies 
breast cancers in a screening population, nor does the algorithm address screening 
mammography interpretation. Additionally, the algorithm was validated using data from 
1994, and it is uncertain if it achieves similar performance with more recent Medicare 
claims.
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We capitalized on the linkage of high-quality mammography and cancer incidence data from 
the Breast Cancer Surveillance Consortium with Medicare claims to evaluate the 
performance of claims-based methods for identifying incident breast cancer that followed 
positive screening mammography. We first assessed the performance the approach described 
by Nattinger et al. (13) within a screening mammography cohort. (Henceforth, we refer to 
this as the Nattinger algorithm.) We then assessed whether classification and regression tree 
analyses could identify an alternative approach with improved performance. We 
hypothesized that claims-derived algorithms could identify incident cancers following true-
positive screening mammography with high predictive value in recent Medicare claims.
METHODS
Data
We used data from Medicare claims files (the Carrier Claims, Outpatient, and Inpatient files) 
and the Medicare denominator file, which provides demographic, enrollment, and vital 
status data. While Medicare mammography claims typically appear in the Carrier file, we 
assessed both the Carrier and Outpatient files to capture the minority of claims present only 
in the Outpatient file (~3%) (14). We used Healthcare Common Procedure Coding System 
(HCPCS) procedure codes to identify bilateral mammograms and procedures occurring 
before and after mammography. Medicare claims also include International Classification of 
Diseases, 9th Edition, Clinical Modification (ICD-9-CM) diagnosis codes, which we used to 
identify breast cancer diagnosis codes and breast symptoms.
Medicare claims from 1998 to 2006 were linked with BCSC mammography data derived 
from regional mammography registries in four states (North Carolina; San Francisco Bay 
Area, CA; New Hampshire; and Vermont) (http://breastscreening.cancer.gov/). Claims and 
BCSC mammography data were matched using a deterministic algorithm derived by the 
National Center for Health Statistics that is based on social security numbers (when 
available), names, and birthdates. Among women aged 65 years and older with a BCSC 
mammogram between 1998 and 2006, 87% were successfully matched to Medicare claims. 
Women who did not successfully match typically received mammography at facilities that 
did not report social security numbers to the BCSC.
BCSC facilities transmit prospectively collected patient and mammography data to regional 
registries, which link the data to breast cancer outcomes ascertained from regional or 
statewide cancer registries and pathology data. Data are pooled at a central Statistical 
Coordinating Center (SCC). BCSC mammography data include information on examination 
purpose (screening vs. diagnostic), radiologist interpretation, and patient socio-
demographics and breast health history. The BCSC has established standard definitions for 
key variables and multiple levels of data quality control and monitoring (15). Each registry 
and the SCC have received institutional review board approval for either active or passive 
consenting processes or a waiver of consent to enroll participants, link data, and perform 
analytic studies. All procedures are Health Insurance Portability and Accountability Act 
(HIPAA) compliant and all registries and the SCC have received a Federal Certificate of 
Confidentiality to protect the identities of patients, physicians, and facilities.
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Subjects
We identified mammograms captured in both Medicare claims and the BCSC among 
women who were aged 68 or older on mammography dates from January 1, 2001 to 
December 31, 2005. We identified screening mammograms (distinguishing them from 
diagnostic mammograms) using a validated claims-based algorithm based upon the HCPCS 
mammogram codes, claims for mammography in the prior nine months, and claims with 
ICD-9-CM codes for breast cancer during the year prior to mammography (9). Relative to a 
BCSC-derived reference standard, the positive predictive value of the algorithm’s screening 
designation was ~95%. We used the claims-based algorithm (rather than BCSC data) to 
identify screening mammograms so that results would be potentially generalizable to other 
Medicare claims-based studies where linkage of claims to mammography registry data is not 
feasible.
We selected mammograms for women with continuous enrollment in fee-for-service 
Medicare (parts A and B) for twelve months after mammography and three years prior to 
mammography, enabling both prospective assessment of outpatient claims for clinical events 
that might indicate incident breast cancer following abnormal screening mammography, and 
retrospective assessment for claims indicating prevalent breast cancer. Hence, we excluded 
women aged 65 to 68 years because only women aged 68 years or greater consistently have 
three years of prior claims. Following Nattinger, et al. (13), we considered a woman to have 
prevalent cancer if any ICD-9-CM codes for invasive breast cancer or ductal carcinoma in-
situ appeared on claims in the three years prior to mammography (see Table, Supplemental 
Digital Content 1, which gives claims and diagnostic codes used in developing study 
variables). Although some women with prevalent breast cancer continue to receive 
screening mammography, we excluded these mammograms so that our sample represented 
women undergoing screening who had no breast cancer in the prior three years. We 
randomly divided the sample into two half-samples, one for training and one for validation 
of classification and regression tree (CART) analyses.
Reference Standard
We used BCSC cancer registry data to identify incident breast cancers and BCSC 
mammography data to identify radiologists’ mammography interpretation. We defined 
incident breast cancers as those with a diagnosis date within one year of the date of 
screening mammography. Following standard BCSC definitions (available at: http://
breastscreening.cancer.gov/data/bcsc_data_definitions.pdf), a positive mammogram was 
defined as one with a Breast Imaging Reporting and Data System (BI-RADS®) assessment 
of 0 (needs additional imaging evaluation), 3 (probably benign finding) with a 
recommendation for immediate follow-up, 4 (suspicious abnormality), or 5 (highly 
suggestive of malignancy)(16). Mammograms with other BI-RADS® assessments were 
defined as negative, because no immediate evaluation was recommended at the time of 
screening mammography. A screen-detected breast cancer was defined as a positive 
mammogram with a diagnosis of incident breast cancer within one year.
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Claims-Based Algorithms for Identifying Incident Screen-Detected Breast Cancers
We first adapted the Nattinger algorithm to identify incident breast cancers during the one 
year following screening mammography (13). The Nattinger algorithm begins by identifying 
“high-probability” cases based on codes for breast cancer diagnoses and therapies during the 
year following the index date (in this instance, the date of mammography). Next, the 
algorithm attempts to exclude women treated for benign breast disease, cancers that were 
metastatic to the breast, and, finally, women with prevalent breast cancer based on breast 
cancer diagnosis codes occurring during three years of claims prior to the index date. We 
classified all cases identified by the algorithm as screen-detected incident cancers. Although 
we recognize that the Nattinger algorithm was not designed to consider mammography 
interpretation, we felt that it was valuable to evaluate its performance in the context of 
recent screening mammography.
We then conducted CART analyses in attempts to identify an algorithm with improved 
performance (17). CART is a non-parametric decision tree methodology that identifies 
sequential binary partitions in independent variables to optimize prediction of the dependent 
variable (in this case, incident breast cancer detected at screening mammography). A 
potential advantage is that CART can specify the best-performing time intervals following 
mammography for ascertaining breast cancer diagnosis or treatment codes following 
incident breast cancers that were detected at mammography.
Potential independent variables for CART analyses were derived from claims on the 
mammogram date or during a one-year post-mammogram follow-up, including: patient age; 
days to any subsequent mammogram; days to diagnosis codes for breast cancer, ductal 
carcinoma in-situ, benign breast tumors, secondary cancers of the breast, or a personal 
history of breast cancer; days to procedural or diagnostic codes for breast biopsies; days to 
any procedural codes for breast-directed surgery (lumpectomy, partial mastectomy, or 
mastectomy), axillary lymph node biopsy or resections; and days to any codes for breast 
radiation (18, 19). (See Table, Supplemental Digital Content 1, for claims and diagnostic 
codes used in developing study variables.)
We performed CART analyses on the training half-sample of mammograms. The CART 
algorithm selected splits in independent variables on the basis of the Gini index, and 
continued growing the tree until no further splits improved the Gini index by more than 
0.0001 (17). To minimize over-fitting, we pruned the tree to optimal complexity based on 
cross-validation.
Analyses of Classification Accuracy
Within the validation sub-sample, we created cross-tabulations to compare the identification 
of incident screen-detected breast cancers using claims-based algorithms versus the 
reference standard. We quantified accuracy using: sensitivity (the proportion of incident 
screen-detected cancers that were identified by the algorithm); specificity (the proportion of 
mammograms without incident screen-detected cancers that were so classified by the 
algorithm); positive predictive value (PPV, or the proportion of algorithmically-identified 
incident screen-detected cancers that were also classified as such by the reference standard); 
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and negative predictive value (the proportion of mammograms classified as having no 
incident screen-detected cancer also classified as having no incident screen-detected cancer 
by the reference standard). As a practical test of the algorithm’s accuracy, we compared 
unadjusted relative rates of breast cancer detection as computed using the CART algorithm 
and BCSC data (i.e., the reference standard) within subgroups based on age, race/ethnicity, 
non-urban vs. urban residence, and Medicaid eligibility. A woman was classified as 
Medicaid eligible if the Medicare denominator file indicated at least one month of Medicaid 
eligibility in the three years before or one year after the index mammogram. Non-urban vs. 
urban residence was determined using the Rural-Urban Commuting Area Code for the zip 
code of the woman’s primary residence. We computed 95% confidence intervals around all 
point estimates. We performed statistical analyses using the rpart package in R, version 
2.12.0 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Mammogram Samples
We identified a sample of 233,044 screening mammograms with linked Medicare claims 
and BCSC records. The mammograms were obtained by 104,997 women who received an 
average of 2.2 mammograms during the study period (range: 1-7). On the date of 
mammography, women had a mean age of 75.2 years (SD: 5.3; range 68 to 104). Based on 
BCSC interpretation and cancer data, radiologists detected breast cancer on 1,384 of the 
mammograms; the breast cancer detection rate in the sample was 5.9 cancers per 1000 
screening mammograms. The patient sample was ethnically diverse with substantial 
representation in both non-urban and urban settings (Table 1).
Performance of Claims-Based Algorithms
Using CART analyses, we identified a claims-based algorithm that classified women based 
on whether breast cancers were detected as screening mammography (Figure 1). Assessing 
claims for one year following screening mammography, the algorithm classifies a 
mammogram as having detected breast cancer if there is a claim diagnosis code for breast 
cancer within 123 days and any claim for breast-directed surgery within one year. 
Alternatively, if there is no claim diagnosis code for breast cancer within 123 days, the 
algorithm classifies a mammogram as having detected incident breast cancer if there is a 
claim diagnosis code for ductal carcinoma in-situ within 286 days and a claim for another 
mammogram within 82 days. The algorithm classifies all other mammograms as not 
detecting incident breast cancer. (See Supplemental Digital Content 2 for programming code 
for implementing the algorithm in R.)
We compared the performance of the Nattinger algorithm and the CART-derived algorithm 
in identifying incident breast cancer detected at screening mammography (Table 2). While 
the Nattinger algorithm had a sensitivity of 83.75%, a specificity 99.86%, and a PPV of 
77.45%,, the CART-dervived algorithm had a sensitivity of 92.89% and slightly higher 
specificity (99.93%). Although small, this difference results in fewer cases falsely classified 
as detected breast cancers using the CART-derived algorithm as compared to the Nattinger 
algorithm and a higher PPV (88.03% vs. 77.45%) .
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In analyses stratified by age, race/ethnicity, Medicaid eligibility, and non-urban vs. urban 
residence, estimates of relative rates of incident detected breast cancer using the algorithm 
were similar to reference standard estimates based on BCSC data (Table 3).
DISCUSSION
In a sample of screening mammograms with corresponding Medicare claims and 
mammography registry data, a claims-based algorithm identified screening mammograms 
with detected incident breast cancers with a sensitivity greater than 90%, a specificity over 
99.9%, and a PPV of 88%. Algorithm performance was generally similar across population 
subgroups and enabled accurate estimates of between-group relative rates of incident breast 
cancer detection.
Both the CART-derived algorithm and the algorithm proposed by Nattinger, et al. had very 
high specificities compared to the BCSC-derived reference standard (13). A high specificity 
is crucial for a cancer detection algorithm. With a rare outcome such as breast cancer, even a 
slight decrement in specificity could markedly diminish the measure’s PPV, as the number 
of false-positives may quickly accumulate in comparison to the number of true-positives. 
Nevertheless, sensitivity is also important to PPV. In this screening mammography cohort, 
the PPV of the CART approach (88.0%) exceeded that of the Nattinger approach (77.5%) 
due to a combination of slightly higher specificity and higher sensitivity (93.9% vs. 83.7%).
The PPV of 88.0% for the CART approach implies that approximately 1 of 9 cancers 
identified by the algorithm as incident detected breast cancers are wrongly identified as 
such. In the validation set, this included 87 cases (of a total 116,522 mammograms). As 
shown in Figure 1, most of these false-positives occurred among women with breast cancer 
diagnosis codes within 123 days and breast-directed surgery within one year of screening 
mammography. Using BCSC data, we found that ~36% (n=31) of these women had interval 
breast cancers that were not detected at screening mammography yet were diagnosed 
clinically within 365 days of screening. Additionally, we found that a small fraction of 
exams (<13%) had breast cancer diagnosis codes on claims but ultimately had benign biopsy 
results; providers for these women may have used breast cancer diagnosis codes while 
“ruling out” breast cancer. (Specific numbers suppressed to protect subject confidentiality.) 
Despite exclusion of mammograms for women with breast cancer diagnosis codes on claims 
during the three prior years, a small fraction of mammograms (<13%) were performed on 
women with prevalent breast cancers based on BCSC data and who received breast-directed 
surgery during the year following screening mammography, conceivably for local 
recurrences.
Meanwhile, the algorithm did not identify 7.1% of women whose breast cancers were truly 
detected at mammography (49 of 689 detected incident cancers in the validation set). As 
shown in Figure 1, many of these women may have had delays in the appearance of 
diagnostic codes for invasive breast cancer or ductal carcinoma in-situ or delays in receipt of 
either breast-directed surgery or subsequent mammography. Nattinger et al. similarly found 
that a small fraction of women with incident breast cancer according to SEER data did not 
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receive breast cancer surgery; these women were more likely than women who received 
surgery to lack breast cancer diagnostic codes in Medicare claims (13).
We recognize that cut-points in the CART algorithm may seem arbitrary, such as the initial 
node in which a breast cancer diagnosis code is assessed as occurring within 123 days of 
screening mammography. While there is no clinical justification for this cut-point, it yields 
the optimal classification of cases as assessed by the Gini index and validated in a testing 
sub-sample. Thus, a shorter or longer cut-point would compromise overall classification 
accuracy, most likely with degradation in PPV. At the same time, we believe the general 
structure and flow of the decision tree is clinically intuitive as one would expect diagnosis 
codes for breast cancer with subsequent procedure codes for treatment to be reliable 
predictors of incident breast cancer. The assessment for procedure codes for subsequent 
mammography among women with diagnosis codes for ductal carcinoma in-situ is perhaps 
less intuitive, although most women with newly diagnosed ductal carcinoma in-situ will 
indeed receive diagnostic mammography within 82 days of screening mammography.
Several potential uses of the CART algorithm are conceivable. First, the algorithm may be 
useful in claims-based studies of screening mammography outcomes, including studies of 
new screening technologies, such as digital mammography or computer-aided detection, on 
incident breast cancer detection. Because the algorithm does not require linkage with cancer 
registry data, investigators may apply it in unlinked Medicare claims, enabling sample sizes 
that would not be achievable with linked data such as the SEER-Medicare data. Second, the 
algorithm could conceivably enable claims-based estimation of radiologist- or facility-level 
quality metrics, specifically breast cancer detection rates, facilitating quality improvement 
efforts in mammography among Medicare enrollees. We recognize that the algorithm’s PPV 
of ~88% does not confer certainty regarding a provider’s true-positive interpretation. The 
algorithm may nevertheless allow identification of provider’s with extremely low breast 
cancer detection rates. In any application, investigators must carefully consider potential 
impacts of algorithmic misclassification on study results and plan suitable sensitivity 
analyses.
Although BCSC data on whether breast cancers were detected at mammography may be 
imperfect, leading to inaccuracy in the reference standard, the BCSC mammography data 
undergo rigorous quality control and are linked with high-quality regional cancer registries. 
Our results also derive from mammography claims of fee-for-service Medicare enrollees 
within four U.S. regional mammography registries. Algorithms may not generalize to non-
Medicare claims or to Medicare enrollees outside these regions. Because study algorithms 
require three years of prior claims to exclude prevalent breast cancers, their validity among 
women younger than age 68 years is uncertain. We also recognize that CART analyses may 
be prone to over-fitting. Nevertheless, our analysis included variables that are clinically 
meaningful, and we cross-validated the CART-derived algorithm within the training sample. 
We also pruned the tree based on theory and practice, and the final tree was highly 
predictive in the test sample. Finally, in late 2014, Medicare will transition from ICD-9 to 
ICD-10 coding. While the mapping of the algorithm’s breast cancer diagnosis and procedure 
codes should be unambiguous, the performance of the algorithm would ideally be re-
evaluated after the transition to ICD-10.
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Study strengths include the inclusion of large mammography claim samples from 
geographically diverse settings that were linked with high-quality external mammography 
data, yielding rigorous validation analyses with excellent precision. Because cancer 
registries such as SEER encompass only 25% of the U.S. population (20), the alternative 
algorithms may enable mammogram sampling for research or quality improvement across 
the entire Medicare program regardless of claims linkage with cancer registry data.
We found that a simple, Medicare claims-based algorithm can identify with high predictive 
value women with incident breast cancers following a positive screening mammogram. 
Applied to Medicare claims alone without cancer registry linkage, the algorithm may be 
useful in claims-based studies of screening mammography. The potential for using the 
algorithm in provider-level quality assessment warrants evaluation.
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Figure 1. Algorithm for identifying incident breast cancers detected at screening mammography
Figure shows algorithmic allocation of 116,522 screening mammograms in the test 
mammogram set with the number allocated and percentage correctly classified in each 
terminal node. An algorithmic classification of “positive” signifies that the algorithm 
classified the mammogram as detecting an incident breast cancer, while a “negative” 
classification signifies that no breast cancer was detected at screening. Timing of all claims 
events are in relation to the date of screening mammography. To protect patient 
confidentiality, cell sizes of less than or equal to 11 are suppressed (and related numbers and 
percentages are given as a range).
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Table 1
Characteristics of Medicare Enrollees Receiving Screening Mammograms
Characteristic
All
(N=233,044
mammograms)
Breast Cancer Not
Detected*
(N=231,660)
Breast Cancer
Detected*
(N=1,384)
n (%) n (%) n (%)
Age
 68-74 117,747 (50.5) 117,100 (50.4) 647 (52.4)
 75-84 101,033 (43.4) 100,383 (43.5) 650 (42.1)
 85+ 14,264 (6.1) 14,177 (6.2) 87 (5.6)
Race/ethnicity
 White, non-Hispanic 187,254 (80.3) 186,117 (80.2) 1137 (82.3)
 Black 16,967 (7.3) 16,856 (7.3) 111 (6.7)
 Asian/Pacific Islander 6,812 (2.9) 6,780 (3.0) 32 (1.6)
 Other/mixed/unknown† 22,011 (9.4) 21,907 (9.5) 104 (9.5)
Year of Mammogram
 2001 43,418 (18.6) 43,177 (18.7) 241 (17.4)
 2002 48,234 (20.7) 47,934 (20.7) 300 (21.0)
 2003 49,270 (21.1) 48,958 (21.1) 312 (21.9)
 2004 46,003 (19.7) 45,734 (19.7) 269 (19.8)
 2005 46,119 (19.8) 45,857 (19.8) 262 (19.9)
Medicaid eligibility
 No 20,2161 (86.8) 200,963 (86.6) 1,198 (88.5)
 Yes 30,883 (13.2) 30,697 (13.4) 186 (11.5)
Non-urban vs. urban
residence ‡
 Non-urban 120,578 (51.7) 119,905 (51.6) 673 (53.9)
 Urban 106,611 (45.8) 105,937 (45.9) 674 (43.7)
 Unknown 5,855 (2.5) 5,818 (2.5) 37 (2.4)
*
Incident breast cancers were identified using regional or statewide cancer registries and were considered detected if Breast Cancer Surveillance 
Consortium radiologists’ Breast Imaging and Reporting Data System (BI-RADS) assessment was either 0, 3 with a recommendation for immediate 
further evaluation, 4, or 5.
†Other race/ethnicity includes American Indian/Alaska Native and Hispanic as well as other race/ethnicities.
‡Non-urban vs. urban residence defined based on Rural Urban Continuum Codes.
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